Triangle177Lu rhPSMA-10.1 (NCT06066437)
177Lu rhPSMA-10.1 trial for Prostate Cancer (NCT06066437). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for men with high-risk prostate cancer that is still in or near the prostate, who are planning surgery to remove it.
The idea: treat before the operation. Lutetium-177 rhPSMA-10.1 is a radioactive medicine that attaches to PSMA, a protein on prostate cancer cells, and delivers radiation to them. Some patients also receive hormone therapy with degarelix.
Doctors measure the radiation dose that reaches the tumor, check safety, and later compare what surgeons find. At MD Anderson in Houston, Brian Chapin leads this small study, called Nautilus.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.